Last edition
News about
CDSCO Cracks Down on Unlicensed IVF Medical Devices
The Central Drugs Standard Control Organisation (CDSCO) has directed its zonal and sub-zonal offices, along with State Licensing Authorities (SLAs), to maintain strict vigilance against the sale of unlicensed medical devices used in In Vitro Fertilisation (IVF) and Assisted Reproductive Technology (ART) procedures.
Wockhardt's Zaynich Gets CDSCO SEC Nod for Gram-Negative Infections
CDSCO’s Subject Expert Committee (SEC) recommends Wockhardt’s Zaynich (Zidebactam/Cefepime) for Gram-negative infections, paving the way for DCGI approval of the novel antibiotic in India.
Medtronic Secures FDA Nod for Stealth AXiS, Advancing Integrated Surgical Technology Manufacturing
Medtronic, a global leader in healthcare technology, has received clearance from the US Food and Drug Administration (FDA) for its Stealth AXiS surgical system for use in cranial and ear, nose, and throat (ENT) procedures.
Takeda's Zasocitinib Shows Strong Skin Clearance in Psoriasis Study
Takeda reports Phase 3 data showing zasocitinib delivers rapid, durable skin clearance in psoriasis, with ~70 percent achieving sPGA 0/1 and early PASI 75 response, with a consistent safety profile.
Arrowhead Pharmaceuticals Reports Long-Term Efficacy, Safety Data for Plozasiran
Arrowhead Pharmaceuticals reports long-term phase 2b data showing plozasiran reduces triglycerides by 83 percent in sHTG patients, with no pancreatitis events and sustained improvements in lipid markers and safety.
Bristol Myers Squibb Reports Positive Phase 3 SCOUT-HCM Trial Results
Bristol Myers Squibb reports positive Phase 3 SCOUT-HCM results showing Camzyos efficacy and safety in adolescents with oHCM, achieving significant LVOT reduction with no new safety concerns.
Eli Lilly Eyes USD 2 Billion AI Drug Discovery Deal with Insilico Medicine
Eli Lilly is set to enter into a deal worth over USD 2 billion with Hong Kong-based Insilico Medicine to accelerate drug discovery using artificial intelligence, signaling a major push toward AI-driven pharmaceutical innovation.
ELMED Life Sciences Raises USD 2.7 Million to Scale Probiotic Manufacturing and Global Expansion
ELMED Life Sciences, a science-driven company specializing in probiotic and biological solutions, has raised USD 2.7 million (approximately INR 25 crore) in a Series A funding round led by AgriSURE Fund, managed by NABVENTURES.
Against this backdrop, Integris MedTech has distinguished itself among Indian peers through its execution speed, disciplined integration approach, and ability to translate acquisitions into scalable market access rather than isolated capacity expansion. Its strategy aligns well with the broader industry shift toward platform-driven growth.
PharmaJet, REDE-TB to Launch Clinical Study on Needle-Free TB Skin Testing Technology
The study will evaluate accuracy, safety and patient acceptance of needle-free Tropis system compared to traditional tuberculin skin test
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy